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 Summary
 Background: To assess inter-observer agreement of revised RECIST criteria (version 1.1) for computed 
tomography assessment of hepatic metastases of breast cancer.
 Material/Methods: A prospective study was conducted in 28 female patients with breast cancer and with at least one 
measurable metastatic lesion in the liver that was treated with 3 cycles of anthracycline-based 
chemotherapy. All patients underwent computed tomography of the abdomen with 64-row multi-
detector CT at baseline and after 3 cycles of chemotherapy for response assessment. Image analysis 
was performed by 2 observers, based on the RECIST criteria (version 1.1).
 Results: Computed tomography revealed partial response of hepatic metastases in 7 patients (25%) by one 
observer and in 10 patients (35.7%) by the other observer, with good inter-observer agreement 
(k=0.75, percent agreement of 89.29%). Stable disease was detected in 19 patients (67.8%) by one 
observer and in 16 patients (57.1%) by the other observer, with good agreement (k=0.774, percent 
agreement of 89.29%). Progressive disease was detected in 2 patients (7.2%) by both observers, with 
perfect agreement (k=1, percent agreement of 100%). The overall inter-observer agreement in the 
CT-based response assessment of hepatic metastasis between the two observers was good (k=0.793, 
percent agreement of 89.29%).
 Conclusions: We concluded that computed tomography is a reliable and reproducible imaging modality for 
response assessment of hepatic metastases of breast cancer according to the RECIST criteria 
(version 1.1).
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Background
Breast cancer is the most common cancer in women 
and is the leading cause of cancer death among women 
worldwide, accounting for 15% of cancer deaths among 
women [1–3]. Patients with newly diagnosed breast cancer 
have modestly improved survival over time. Twenty to 
thirty percent of patients with early breast cancer will 
eventually relapse with distant metastases [4]. The medi-
an survival of patients with metastatic breast cancer is 
approximately 24 months. Hepatic metastases occur in 
about 50% of patients with metastatic breast cancer. Early 
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identification of patients with metastatic breast cancer 
who do not respond to systemic treatment is important in 
order to avoid unnecessary drug-related toxicities [4,5].
Different imaging modalities are used for the assessment 
of hepatic metastases in patients with breast cancer [6–9]. 
Ultrasound is a simple imaging modality for initial diag-
nosis, but it is operator dependent [7,8]. Positron emission 
tomography and/or computed tomography are sensitive 
methods for detection of hepatic metastases, but they are 
associated with radiation exposure and are expensive [7–9]. 
Different pulse sequences of magnetic resonance imaging 
(MRI) are used for the assessment of hepatic metastases, 
such as diffusion-weighted MR imaging, but MRI is an 
expensive imaging technique for a serial follow up [10–12]. 
Currently, computed tomography is considered as an essen-
tial imaging modality for the assessment and measurement 
of lesions in patients who are selected for response assess-
ment. The main advantages of computed tomography are 
its availability, accepted cost, short scanning time, and the 
possibility of post scanning processing [13–16].
The Response Evaluation Criteria in Solid Tumor guide-
lines (RECIST) were published in 2000. The RECIST criteria 
defined the minimum size of measurable lesions, specified 
the number of lesions and applicable imaging techniques, 
and described unidimensional measurements for the evalu-
ation of tumor burden [17–19].
Aim of the work
To assess inter-observer agreement of the revised RECIST 
criteria (version 1.1) for CT-based assessment of hepatic 
metastases of breast cancer.
Material and Methods
Institutional review board approval was obtained, and an 
informed consent was obtained from all patients. This pro-
spective study was carried among 32 female patients in 
the period between January 2012 and December 2016. All 
included patients had pathologically proven breast cancer 
and at least one measurable metastatic lesion in the liver 
that was treated with three cycles of anthracycline-based 
chemotherapy. Four patients were excluded due to previ-
ous exposure to anthracycline (one patient) and contrain-
dications to anthracycline treatment (3 patients). In total, 
the study included 28 female patients s (mean age of 48.39 
years; age range: 22–72 years) who underwent CT of the 
abdomen before and after 3 cycles of anthracycline-based 
chemotherapy. The pathological subtypes of breast cancer 
were as follows, infiltrating duct carcinoma – 24 (85.7%), 
infiltrating lobular carcinoma – 3 (10.7%), and mucinous 
carcinoma – 1 (3.6%).
All patients were examined with a 64-MDCT scanner 
(Brilliance 64, Philips Medical Systems, Cleveland, OH, 
USA). Non-ionic contrast was injected intravenously 
through a power injector (1.5 ml/kg) at a rate of 3–5 ml/
sec. The CT examination of the abdomen was performed in 
the supine position. Scanning started 30-60 seconds after 
contrast injection. A collimation of 64×0.6 mm, with 0.5 
second rotation time, and a pitch factor of 1.4 were used. 
The tube voltage was 120 kV, 100-200 mAs. Images were 
reconstructed with an overlapping technique in the axial 
plane with an effective slice thickness of 1–1.5 mm and a 
reconstruction increment of 0.7–0.8 mm.
The analysis of computed tomography images was per-
formed by one radiologist (AA) and one oncologist (F) who 
were blinded to the clinical presentation and data of the 
patients. Response assessment was performed accord-
ing to the revised RECIST guideline (version 1.1) [17]. 
Disappearance of all target lesions was regarded as com-
plete response (CR), a decrease of at least 30% in the 
sum of diameters of target lesions was regarded as par-
tial response (PR), an increase of at least 20% in the sum 
of diameters of the target lesions or appearance of new 
lesions was regarded as progressive disease (PD), and no 
change in size was regarded as stable disease (SD).
Statistical analysis of data was performed with the 
Statistical Package for Social Science (SPSS) software, ver-
sion 16. The inter-observer agreement was expressed with 
the kappa (k) statistic with 95% confidence intervals (CI). P 
value <0.05 was considered to indicate statistical signifi-
cance. The k statistic is the amount of observed agreement. 
A k value of 0.81 to 1.0 is an excellent agreement, 0.61 to 
0.80 is good agreement, 0.41 to 0.60 is moderate agreement, 
0.21 to 0.40 is fair agreement, and 0.0 to 0.20 represents 
slight agreement, and a k value of 1.0 represents perfect 
agreement.
Results
Partial response (Figure 1) was detected in 7 patients (25%) 
by one observer and in 10 patients (35.7%) by the other 
observer, with good agreement (k=0.750, percent agree-
ment of 89.29%). Stable disease (Figure 2) was detected 
in 19 patients (67.8%) by one observer and in 16 patients 
(57.1%) by the other observer, with good agreement 
(k=0.774, percent agreement of 89.29%). Progressive dis-
ease (Figure 3) was detected in 2 patients (7.2%) by both 
observers, with perfect agreement (k=1, percent agreement 
of 100%) (Table 1). The overall inter-observer agreement 
in response assessment between both observers was good 
(k=0.793, percent agreement of 89.29%).
Disscusion
The main finding of the study is good overall inter-observer 
agreement in response assessment of hepatic metastasis 
in patients with breast cancer (k=0.793, percent agree-
ment=89.29). In practice, post treatment imaging of hepat-
ic metastases varies widely by center and remains variable 
despite the consensus guidelines.
In this study, there was good inter-observer agreement 
with respect to the CT-based assessment of hepatic metas-
tases of breast cancer. Few available studies discuss the 
inter-observer agreement of computed tomography assess-
ment in hepatic and other malignancies [20–23]. One study 
reported that evaluation of 80 lymph nodes, 120 pulmo-
nary lesions, and 120 hepatic lesions by 17 radiologists 
with variable levels of experience was characterized by 
excellent inter-observer agreement with respect to hepatic 
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lesions. Those authors added that larger lesion size and 
greater reader experience resulted in a higher consistency 
of measurements [20]. Abdel Razek et al. added that the 
overall inter-observer agreement in staging and response 
assessment of lymphoma after a complete course of treat-
ment, that was carried out with whole-body computed 
Figure 1.  Partial response: (A) Baseline axial CT of the abdomen shows multiple hepatic metastatic focal lesions in a patient with breast cancer 
before chemotherapy. (B) Follow-up axial contrast CT shows regression of hepatic focal lesions after chemotherapy.
A B
Figure 2.  Stable disease: (A) Baseline axial contrast CT scan of the abdomen shows hepatic metastatic lesions before chemotherapy. (B) Follow-up 
axial contrast CT scan after chemotherapy shows stable appearance of the hepatic focal lesions.
A B
Figure 3.  Progressive disease: (A) Baseline axial CT scan of the abdomen shows small metastatic focal lesions in the liver before chemotherapy. 
(B) Follow-up axial CT scan after chemotherapy shows progression of hepatic focal lesions.
A B
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tomography, was excellent (k=0.90) [21]. Another study 
reported that computed tomography revealed excellent 
inter-observer agreement among three blinded reviewers 
in assessing small hepatocellular carcinoma [22]. Another 
study added that three-dimensional volumetric algorithms 
and assessments based on RECIST 1.1 showed a discordant 
classification of treatment response in 10–21% of patients 
with hepatic metastases [23].
In this study, the used RECIST (version 1) criteria standard-
ized and simplified the assessment of treatment response. 
One study reported that the RECIST guidelines updated 
the WHO definitions with the objective of re-unifying cri-
teria of response assessment [17]. Another study added 
that RECIST guidelines could be used when working on 
selection of target lesions in terms of number, size, locali-
zation, and measurability [18,19]. Since its introduction, 
the RECIST 1.0 criteria have been extensively adopted in 
clinical trials and have remained the most commonly used 
method of treatment response evaluation [17–19].
There were a few limitations of this study. First, the sam-
ple size was small and therefore further studies with larger 
numbers of patients that will analyze pulmonary, nodal, 
and hepatic metastases are recommended. Second, this 
study was performed with a 64-row CT scanner, which 
was associated with radiation exposure. Further studies 
with the application of advanced computed tomography 
techniques, such as whole-body computed tomography [24], 
CT perfusion [25–27], dual energy computed tomogra-
phy [28], and advanced magnetic resonance sequences, like 
diffusion-weighted MR imaging [29–31], diffusion tensor 
MR imaging [32], dynamic contrast enhanced MR imag-
ing [33], dynamic susceptibility contrast-enhanced MR 
imaging [34,35], will improve outcomes, as they can detect 
small hepatic focal lesions, thereby improving prognosis 
and survival.
Conclusions
We concluded that computed tomography is a reliable and 
reproducible imaging modality for response assessment of 
liver metastases in patients with breast cancer.
Category 1
st 
reader
2nd 
reader K 95% CI
Percent 
agreement
P 
value
PR  7 (25%)  10 (35.7%) 0.75 0.491–1.0 89.29 0.001
SD  19 (67.8%)  16 (57.1%) 0.774 0.539–1.0 89.29 0.001
PD  2 (7.2%)  2 (7.2%) 1.00 1.00–1.0 100.0 0.001
Overall  28 (100%)  28 (100%) 0.793 0.573–1.0 89.29 0.001
Table 1.  Inter-observer agreement with 95%% CI and percent agreement of response assessment of hepatic metastases in patients with breast 
cancer.
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